Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program

Marco Ladetto,Chiara Lobetti Bodoni,Barbara Mantoan,Manuela Ceccarelli,Carola Boccomini,Elisa Genuardi,Annalisa Chiappella,Luca Baldini,G. Rossi,Alessandro Pulsoni,F. Di Raimondo,Luigi Rigacci,Antonello Pinto,Sara Galimberti,Alessia Bari,Delia Rota Scalabrini,Antonella Ferrari,F. Zaja,Andrea Gallamini,Giorgina Specchia,P. Musto,F.G. Rossi,Enrica Gamba,Andrea Evangelista,U Vitolo

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program

2013

We assessed the prognostic value of minimal residual disease (MRD) within the ML17638 phase 3 trial from the Fondazione Italiana Linfomi, investigating the role of rituximab maintenance in elderly follicular lymphoma (FL) patients after a brief first-line chemoimmunotherapy. MRD for the bcl-2/IgH

Keywords:

Follicular lymphoma
Minimal residual disease
Bone marrow
Follicular phase
Combined Modality Therapy
Rituximab
Hematology
Chemoimmunotherapy
Immunology
Medicine
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations